Novo Nordisk: switching to Tresiba benefits patients.
(CercleFinance.com) - Data from a study has showed that switching to Novo Nordisk's Tresiba from another basal insulin benefits people with diabetes, regardless of whether or not their blood sugar levels are controlled.
Switching to Tresiba reduces the rate of hypoglycaemia by 67% in people with controlled blood sugar levels, the Danish drugmaker said.
In people with diabetes whose blood sugar was too high, switching to Tresiba also significantly improved blood sugar levels, Novo Nordisk said.
"This confirms that the benefits of Tresiba® seen in clinical trials are being reproduced in clinical practice," said Mads Krogsgaard Thomsen, chief scientific officer at Novo Nordisk.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Switching to Tresiba reduces the rate of hypoglycaemia by 67% in people with controlled blood sugar levels, the Danish drugmaker said.
In people with diabetes whose blood sugar was too high, switching to Tresiba also significantly improved blood sugar levels, Novo Nordisk said.
"This confirms that the benefits of Tresiba® seen in clinical trials are being reproduced in clinical practice," said Mads Krogsgaard Thomsen, chief scientific officer at Novo Nordisk.
Copyright (c) 2017 CercleFinance.com. All rights reserved.